<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071628</url>
  </required_header>
  <id_info>
    <org_study_id>TGVT-1301</org_study_id>
    <nct_id>NCT02071628</nct_id>
  </id_info>
  <brief_title>Study for Validation of In-vitro Turbidometric Platelet Aggregation Assay Using Human Blood in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <brief_summary>
    <textblock>
      This study is designed for validation of in-vitro platelet aggregation assay using human&#xD;
      blood in healthy volunteers. 32ml blood, 2ml for complete blood count test and 30ml for&#xD;
      platelet aggregation assay, was collected from ten subjects, respectively.&#xD;
&#xD;
      Preparation of Platelet Rich Plasma (PRP):&#xD;
&#xD;
        1. Collect human blood using 21g butterfly syringe and dilute 9:1 into 3.8% sodium citrate&#xD;
           vacutainer vials.&#xD;
&#xD;
        2. Prepare platelet rich plasma (PRP) by centrifuging blood at 100 x g for 15 minutes at&#xD;
           room temperature. Using a plastic transfer pipette, carefully transfer and combine PRP&#xD;
           from multiple vacutainer tubes (if required) into a 15 mL conical tube.&#xD;
&#xD;
        3. PRP is removed re-centrifuge remaining blood in vacutainer tubes at 2000 x g for 15&#xD;
           minutes at room temp. to obtain platelet poor plasma (PPP). Transfer PPP to 15 mL&#xD;
           conical tube.&#xD;
&#xD;
        4. Measure platelet count in combined PRP using Z1 Coulter Particle Counter or similar&#xD;
           product. Adjust platelet count to a final concentration of 300,000 +- 10,000 platelets&#xD;
           in PRP using PPP.&#xD;
&#xD;
      Aggregation Measurement:&#xD;
&#xD;
      Aggregation is measured using a model 490-X Chrono-Log Aggregometer or similar product. PPP&#xD;
      is used as a reference to establish 100% optical transmission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal platelet aggregation(MPA) for the TRAP and 5-HT baseline aggregation response and the 5-HT amplification of TRAP-induced aggregation</measure>
    <time_frame>Up to 6months</time_frame>
    <description>Calculate each maximal platelet aggregation(MPA) for the TRAP and 5-HT baseline aggregation response and the 5-HT amplification of TRAP-induced aggregation, respectively. Compare the results with previous datas to evaluate the analysis machine and the assay methods.</description>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Validation of In-vitro Turbidometric Platelet Aggregation Assay</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adult voulteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20-50years old&#xD;
&#xD;
          -  must be able to consent voluntarily&#xD;
&#xD;
          -  consent to keep the study terms of obedience&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  blood coagulation disorder or bleeding disorder&#xD;
&#xD;
          -  blood donation within 60 days or blood transfusion within 30 days before screening&#xD;
&#xD;
          -  smoker or who stopped smoking within 1month before screening&#xD;
&#xD;
          -  administration of drugs such as anticoagulants or antiplatelets or alcohol within 14&#xD;
             days before screening&#xD;
&#xD;
          -  eligibility failure under investigator's judgements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>February 22, 2014</last_update_submitted>
  <last_update_submitted_qc>February 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kyun-Seop Bae</investigator_full_name>
    <investigator_title>Asan Medical Center</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

